{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:30:42Z","timestamp":1793302242716,"version":"4.5.0"},"reference-count":47,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070908"],"award-info":[{"award-number":["82070908"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-014"],"award-info":[{"award-number":["2022-PUMCH-B-014"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-006"],"award-info":[{"award-number":["2022-PUMCH-D-006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Denosumab is a potential therapeutic agent for osteogenesis imperfecta (OI), but its efficacy and safety remain unclear in children with OI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to investigate the effects of denosumab on bone mineral density (BMD), spinal morphometry, and safety in children with OI compared with zoledronic acid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this prospective study, 84 children or adolescents with OI were randomized to receive denosumab subcutaneous injection every 6 months or zoledronic acid intravenous infusion once. Changes of BMD and its Z-score, vertebral shape, serum levels of calcium and bone turnover biomarkers were assessed during the 1-year treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After 12 months of treatment, BMD at the lumbar spine, femoral neck, and total hip significantly increased by 29.3%, 27.8%, and 30.2% in the denosumab group, and by 32.2%, 47.1%, and 41.1% in the zoledronic acid group (all P &amp;lt; .001 vs baseline). Vertebral height and projection area significantly increased after denosumab and zoledronic acid treatment. Rebound hypercalcemia was found to be a common and serious side effect of denosumab, of which 14.3% reached hypercalcemic crisis. Rebound hypercalcemia could be alleviated by switching to zoledronic acid treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with denosumab or zoledronic acid is beneficial in increasing BMD and improving the spinal morphometry of children with OI. However, denosumab should be used with caution in pediatric patients with OI because of its common and dangerous side effect of rebound hypercalcemia. The appropriate dosage and dosing interval of denosumab need to be further explored in children with OI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad732","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T21:26:38Z","timestamp":1704921998000},"page":"1827-1836","source":"Crossref","is-referenced-by-count":33,"title":["Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta\u2014the First Prospective Comparative Study"],"prefix":"10.1210","volume":"109","author":[{"given":"Jiayi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-0337","authenticated-orcid":false,"given":"Lei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-3462","authenticated-orcid":false,"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0395-8789","authenticated-orcid":false,"given":"Ou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8634-2252","authenticated-orcid":false,"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"10028","key":"2024061623522315800_dgad732-B1","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"2024061623522315800_dgad732-B2","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Osteogenesis imperfecta: an update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024061623522315800_dgad732-B3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/endrev\/bnab017","article-title":"Osteogenesis imperfecta: mechanisms and signaling pathways connecting classical and rare OI types","volume":"43","author":"Jovanovic","year":"2022","journal-title":"Endocr Rev"},{"issue":"12","key":"2024061623522315800_dgad732-B4","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ajmg.a.61366","article-title":"Nosology and classification of genetic skeletal disorders: 2019 revision","volume":"179","author":"Mortier","year":"2019","journal-title":"Am J Med Genet A"},{"issue":"9902","key":"2024061623522315800_dgad732-B5","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"2024061623522315800_dgad732-B6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2024061623522315800_dgad732-B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2016.02.015","article-title":"Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate","volume":"87","author":"Lindahl","year":"2016","journal-title":"Bone"},{"key":"2024061623522315800_dgad732-B8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bone.2019.06.011","article-title":"Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta","volume":"127","author":"Li","year":"2019","journal-title":"Bone"},{"issue":"5","key":"2024061623522315800_dgad732-B9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024061623522315800_dgad732-B10","first-page":"D5088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2024061623522315800_dgad732-B11","doi-asserted-by":"crossref","first-page":"115914","DOI":"10.1016\/j.bone.2021.115914","article-title":"Osteogenesis imperfecta in children","volume":"148","author":"Arshad","year":"2021","journal-title":"Bone"},{"issue":"12","key":"2024061623522315800_dgad732-B12","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024061623522315800_dgad732-B13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024061623522315800_dgad732-B14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1196\/annals.1365.036","article-title":"Bisphosphonates","volume":"1092","author":"Lambrinoudaki","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2024061623522315800_dgad732-B15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone"},{"issue":"18","key":"2024061623522315800_dgad732-B16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"2024061623522315800_dgad732-B17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"2024061623522315800_dgad732-B18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2024061623522315800_dgad732-B19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2213-8587(22)00012-2","article-title":"Osteoporosis in men","volume":"10","author":"Vilaca","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2024061623522315800_dgad732-B20","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2013a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"12","key":"2024061623522315800_dgad732-B21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/jcm7120479","article-title":"Efficacy and safety of denosumab therapy for osteogenesis Imperfecta patients with osteoporosis-case series","volume":"7","author":"Kobayashi","year":"2018","journal-title":"J Clin Med"},{"issue":"1","key":"2024061623522315800_dgad732-B22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13023-019-1197-z","article-title":"Individualized treatment with denosumab in children with osteogenesis imperfecta\u2014follow up of a trial cohort","volume":"14","author":"Hoyer-Kuhn","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2024061623522315800_dgad732-B23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2024061623522315800_dgad732-B24","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"2","key":"2024061623522315800_dgad732-B25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/13543784.2021.1863371","article-title":"Safety and pharmacokinetics of a biosimilar of denosumab (KN012): phase 1 and bioequivalence study in healthy Chinese subjects","volume":"30","author":"Zhang","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"2024061623522315800_dgad732-B26","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1210\/clinem\/dgac366","article-title":"Relationship of pathogenic mutations and responses to zoledronic acid in a cohort of osteogenesis imperfecta children","volume":"107","author":"Sun","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024061623522315800_dgad732-B27","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00198-017-4143-8","article-title":"Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing","volume":"28","author":"Liu","year":"2017","journal-title":"Osteoporos Int"},{"issue":"12","key":"2024061623522315800_dgad732-B28","doi-asserted-by":"crossref","first-page":"e82098","DOI":"10.1371\/journal.pone.0082098","article-title":"Bone mineral density of the spine in 11,898 Chinese infants and young children: a cross-sectional study","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"2024061623522315800_dgad732-B29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024061623522315800_dgad732-B30","first-page":"487","article-title":"[Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years]","volume":"47","author":"Li","year":"2009","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"7","key":"2024061623522315800_dgad732-B31","first-page":"493","article-title":"[Body mass index growth curves for Chinese children and adolescents aged 0 to 18 years]","volume":"47","author":"Li","year":"2009","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"9124","key":"2024061623522315800_dgad732-B32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0140-6736(97)12331-5","article-title":"Electrolyte quintet: calcium","volume":"352","author":"Bushinsky","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"2024061623522315800_dgad732-B33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.amjmed.2014.09.030","article-title":"Hypercalcemic crisis: a clinical review","volume":"128","author":"Ahmad","year":"2015","journal-title":"Am J Med"},{"key":"2024061623522315800_dgad732-B34","doi-asserted-by":"crossref","unstructured":"Liu JY, Lin XY, Sun L, et al Supplementary Figure 1-2. Data from \u201cSafety and efficacy of denosumab in children with osteogenesis imperfecta- the first prospective comparative study\u201d. Figshare. Deposited 26 December 2023. https:\/\/doi.org\/10.6084\/m9.figshare.24563125.v4","DOI":"10.1210\/clinem\/dgad732"},{"key":"2024061623522315800_dgad732-B35","doi-asserted-by":"crossref","first-page":"116788","DOI":"10.1016\/j.bone.2023.116788","article-title":"Drug-induced osteopetrosis","volume":"173","author":"Whyte","year":"2023","journal-title":"Bone"},{"issue":"9419","key":"2024061623522315800_dgad732-B36","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"2024061623522315800_dgad732-B37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4158\/EP171910.OR","article-title":"Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study","volume":"24","author":"Lv","year":"2018","journal-title":"Endocr Pract"},{"issue":"12","key":"2024061623522315800_dgad732-B38","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","article-title":"Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment","volume":"27","author":"Trejo","year":"2016","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024061623522315800_dgad732-B39","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American college of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"7","key":"2024061623522315800_dgad732-B40","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2024061623522315800_dgad732-B41","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024061623522315800_dgad732-B42","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1359\/jbmr.080511","article-title":"Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases","volume":"23","author":"Whyte","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024061623522315800_dgad732-B43","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024061623522315800_dgad732-B44","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1210\/en.2006-0403","article-title":"Exogenous 1,25-dihydroxyvitamin D3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the 1alpha-hydroxylase and parathyroid hormone null alleles","volume":"147","author":"Xue","year":"2006","journal-title":"Endocrinology"},{"issue":"16","key":"2024061623522315800_dgad732-B45","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: a review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"2024061623522315800_dgad732-B46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00223-023-01065-4","article-title":"Mitigating the denosumab-induced rebound phenomenon with alternating short- and long-acting anti-resorptive therapy in a young boy with severe OI type VI","volume":"112","author":"Seale","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2024061623522315800_dgad732-B47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12519-020-00378-w","article-title":"Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?","volume":"16","author":"Sydlik","year":"2020","journal-title":"World J Pediatr"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad732\/55378698\/dgad732.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/7\/1827\/58235449\/dgad732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/7\/1827\/58235449\/dgad732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T23:53:18Z","timestamp":1718581998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/7\/1827\/7515043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad732","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,1,10]]}}}